



3FW

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

ELECTION UNDER 35 U.S.C. §121
Examining Group 1648
Patent Application
Docket No. USF-T187XC1
Serial No. 10/734,548

on November 3, 2006

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Myron G. Hill
Art Unit : 1648
Applicants : Shyam S. Mohapatra, Homero Gabriel San Juan Vergara
Serial No. : 10/734,548
Filed : December 12, 2003
For : Protein Kinase C as a Target for the Treatment of Respiratory Syncytial Virus

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ELECTION UNDER 35 U.S.C. §121


Sir:

In response to the written restriction requirement dated October 5, 2006, the applicants hereby elect with traverse to prosecute the Group I claims, e.g., claims 1-13, drawn to a method of inhibiting RSV infection in a patient. In response to the species restriction, the applicants further elect PKC-alpha/beta pseudosubstrate peptide as the single compound, antisense-oligonucleotide as the single type of PKC inhibitor, and interfering RNA as the polynucleotide inhibitor.

A Preliminary Amendment is being submitted with this Election.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
P.O. Box 142950
Gainesville, FL 32614-2950

GPL/mv

Attachment: Preliminary Amendment